Catalyst Wire Dossier Catalyst Wire Dossier

Rebamipide 2% ophthalmic suspension

rebamipide · Kubota Vision Inc.
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Rebamipide 2% ophthalmic suspension, covering 2012-01-11 to 2012-01-11. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Subjects With Dry Eye - Effects on Central Cornea [Phase 2]

See pricing